Isis Pharmaceuticals (ISIS) 32.31 $ISIS
Company News for August 05, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 9:10AM CDT
Companies in the News are: I,BWP,ALR,ISIS
Insider Trading Alert - GPN, UHS And ISIS Traded By Insiders
at The Street - Mon Aug 04, 9:30AM CDT
Stocks with insider trader activity include GPN, UHS and ISIS
Isis Reports Financial Results and Highlights for Second Quarter 2014
PR Newswire - Mon Aug 04, 7:30AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today reported pro forma net operating income of $1.1 million and a pro forma net operating loss (NOL) of $21.5 million for the three and six months ended June 30, 2014, respectively, compared to an NOL of $5.3 million and $799,000 for the same periods in 2013. Isis' pro forma operating income in the second quarter of 2014 was primarily driven by more than $40 million of milestone payments from partners the Company earned during the second quarter. On a GAAP basis, Isis reported a loss from operations of $6.7 million and $36.3 million for the three and six months ended June 30, 2014, respectively, compared to a loss from operations of $7.9 million and $6.3 million for the three and six months ended June 30, 2013. Isis ended the first half of 2014 with approximately $591 million in cash, not including approximately $41 million that Isis received after the quarter ended, compared to $657 million at December 31, 2013.
Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy
PR Newswire - Fri Aug 01, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the initiation of a pivotal Phase 3 study evaluating ISIS-SMNRx in infants with spinal muscular atrophy (SMA), the most common genetic cause of infant mortality. Isis plans to dose the first infant in this study within the next few weeks, at which time Isis will earn an $18 million milestone payment from its development partner, Biogen Idec. The Phase 3 study, ENDEAR, is the first of several planned studies in a broad and comprehensive late-stage clinical development program for ISIS-SMNRx. Isis plans to initiate a second pivotal study in children with SMA later this year.
Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call
PR Newswire - Mon Jul 28, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast:
Isis Pharma Initiates Phase II Study on ISIS-APO(a) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 5:50PM CDT
Isis Pharmaceuticals, Inc. (ISIS) initiated a phase II study on ISIS-APO(a) in patients suffering from high lipoprotein(a) -- Lp(a).
ISIS Pharmaceuticals, Inc. is The Best Stock Today
David Williamson, The Motley Fool - Motley Fool - Sun Jul 20, 4:20PM CDT
The Motley Fool's Better Stock Today tournament has declared a winner! Among the 32 companies pitted against each other our reader's voices your voice were heard loud and clear : Isis Pharmaceuticals is the best stock today. David Williamson,...
Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-APO(a) Rx in Patients with High Lp(a)
PR Newswire - Thu Jul 17, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 2 study evaluating ISIS-APO(a)Rx in patients with high lipoprotein(a), or Lp(a), an independent risk factor for cardiovascular disease. Patients with high levels of Lp(a) have an increased risk of atherosclerosis, coronary heart disease, aortic stenosis, heart attack and stroke. ISIS-APO(a)Rx is designed to reduce Lp(a) by inhibiting the production of apolipoprotein(a). Isis plans to develop ISIS-APO(a)Rx to treat patients with high Lp(a) levels who are at high risk of experiencing life-threatening cardiovascular events.
Isis Pharmaceuticals receives USD1m milestone for advancing ISIS-TTR Rx for treatment of familial amyloid polyneuropathy
M2 - Wed Jul 16, 9:08AM CDT
Novel drug company Isis Pharmaceuticals (NasdaqGS:ISIS) said on Wednesday that it has earned a USD1m milestone payment related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).
Critical Alerts For Cninsure, Freeport-McMoRan, Level 3 Communications, Electronic Arts, and Isis Pharmaceuticals Released By InvestorsObserver
PR Newswire - Wed Jul 16, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CISG, FCX, LVLT, EA, and ISIS.
Isis Pharmaceuticals Earns $1 Million from GSK for Advancing ISIS-TTR Rx
PR Newswire - Wed Jul 16, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).
Biotech Equities Technical Momentum -- Research on Organovo, Prana Biotechnology, Isis Pharma, and Pharmacyclics
PR Newswire - Mon Jul 14, 6:04AM CDT
On Friday, July 11, 2014, the NASDAQ Composite ended at 4,415.49, up 0.44%, the Dow Jones Industrial Average advanced 0.17%, to finish the day at 16,943.81, and the S&P 500 closed at 1,967.57, up 0.15%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 712.90, up 0.14%, with the index also advancing 10.01% in the previous three months. Investor-Edge has initiated coverage on the following equities: Organovo Holdings Inc. (NYSE MKT: ONVO), Prana Biotechnology Ltd (NASDAQ: PRAN), Isis Pharmaceuticals Inc. (NASDAQ: ISIS) and Pharmacyclics Inc. (NASDAQ: PCYC). Free technical research on ONVO, PRAN, ISIS and PCYC can be downloaded upon signing up at:
Is This the Crown Jewel of the ISIS Pipeline?
Brian Wilson, The Motley Fool - Motley Fool - Tue Jul 08, 1:01PM CDT
ISIS Pharmaceuticals is a drug developer that is most famous for its RNA interference (RNAi) technology. Although early clinical progress in RNAi was slow due to crippling toxicity and delivery issues, ISIS Pharma (and its peers) have truly refined...
Watch for Isis Pharmaceuticals to Potentially Rebound After Falling 6.71% Yesterday
Comtex SmarTrend(R) - Mon Jul 07, 6:04PM CDT
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $33.03 to a high of $35.36. Yesterday, the shares fell 6.7%, which took the trading range below the 3-day low of $34.51 on volume of 2.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Isis Pharmaceuticals to Speak at Pharmica Consulting's West Coast SharePoint Conference
PRWeb - Mon Jul 07, 4:31AM CDT
As part of its continued service to the industry, Pharmica will host its 11th SharePoint conference in San Diego, CA on September 30 and October 1, 2014. The two-day conference will highlight real-world case studies and feature interactive discussions that help business users better understand how SharePoint can be leveraged to streamline everyday activities.
19.0% Return Seen to Date on SmarTrend Isis Pharmaceuticals Call (ISIS)
Comtex SmarTrend(R) - Wed Jul 02, 5:09PM CDT
SmarTrend identified an Uptrend for Isis Pharmaceuticals (NASDAQ:ISIS) on May 27th, 2014 at $29.71. In approximately 1 month, Isis Pharmaceuticals has returned 19.00% as of today's recent price of $35.35.
Isis Pharmaceuticals earns USD1m pre-licensing payment for Hepatitis B Virus Programme
M2 - Wed Jul 02, 7:39AM CDT
Novel drugs company Isis Pharmaceuticals (NasdaqGS:ISIS) said on Wednesday that it has earned a USD1m for the advancement of the programme to develop antisense drugs to treat hepatitis B virus (HBV) from GlaxoSmithKline (GSK).
Isis Pharmaceuticals Earns $1 Million From GSK for Advancing Hepatitis B Virus Program
PR Newswire - Wed Jul 02, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million payment from GlaxoSmithKline (GSK) related to the advancement of its program to develop antisense drugs to treat hepatitis B virus (HBV).
Company News for August 05, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 9:10AM CDT
Companies in the News are: I,BWP,ALR,ISIS
Insider Trading Alert - GPN, UHS And ISIS Traded By Insiders
at The Street - Mon Aug 04, 9:30AM CDT
Stocks with insider trader activity include GPN, UHS and ISIS
Isis Reports Financial Results and Highlights for Second Quarter 2014
PR Newswire - Mon Aug 04, 7:30AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today reported pro forma net operating income of $1.1 million and a pro forma net operating loss (NOL) of $21.5 million for the three and six months ended June 30, 2014, respectively, compared to an NOL of $5.3 million and $799,000 for the same periods in 2013. Isis' pro forma operating income in the second quarter of 2014 was primarily driven by more than $40 million of milestone payments from partners the Company earned during the second quarter. On a GAAP basis, Isis reported a loss from operations of $6.7 million and $36.3 million for the three and six months ended June 30, 2014, respectively, compared to a loss from operations of $7.9 million and $6.3 million for the three and six months ended June 30, 2013. Isis ended the first half of 2014 with approximately $591 million in cash, not including approximately $41 million that Isis received after the quarter ended, compared to $657 million at December 31, 2013.
Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy
PR Newswire - Fri Aug 01, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the initiation of a pivotal Phase 3 study evaluating ISIS-SMNRx in infants with spinal muscular atrophy (SMA), the most common genetic cause of infant mortality. Isis plans to dose the first infant in this study within the next few weeks, at which time Isis will earn an $18 million milestone payment from its development partner, Biogen Idec. The Phase 3 study, ENDEAR, is the first of several planned studies in a broad and comprehensive late-stage clinical development program for ISIS-SMNRx. Isis plans to initiate a second pivotal study in children with SMA later this year.
Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call
PR Newswire - Mon Jul 28, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast:
Isis Pharma Initiates Phase II Study on ISIS-APO(a) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 5:50PM CDT
Isis Pharmaceuticals, Inc. (ISIS) initiated a phase II study on ISIS-APO(a) in patients suffering from high lipoprotein(a) -- Lp(a).
ISIS Pharmaceuticals, Inc. is The Best Stock Today
David Williamson, The Motley Fool - Motley Fool - Sun Jul 20, 4:20PM CDT
The Motley Fool's Better Stock Today tournament has declared a winner! Among the 32 companies pitted against each other our reader's voices your voice were heard loud and clear : Isis Pharmaceuticals is the best stock today. David Williamson,...
Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-APO(a) Rx in Patients with High Lp(a)
PR Newswire - Thu Jul 17, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 2 study evaluating ISIS-APO(a)Rx in patients with high lipoprotein(a), or Lp(a), an independent risk factor for cardiovascular disease. Patients with high levels of Lp(a) have an increased risk of atherosclerosis, coronary heart disease, aortic stenosis, heart attack and stroke. ISIS-APO(a)Rx is designed to reduce Lp(a) by inhibiting the production of apolipoprotein(a). Isis plans to develop ISIS-APO(a)Rx to treat patients with high Lp(a) levels who are at high risk of experiencing life-threatening cardiovascular events.
Isis Pharmaceuticals receives USD1m milestone for advancing ISIS-TTR Rx for treatment of familial amyloid polyneuropathy
M2 - Wed Jul 16, 9:08AM CDT
Novel drug company Isis Pharmaceuticals (NasdaqGS:ISIS) said on Wednesday that it has earned a USD1m milestone payment related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).
Critical Alerts For Cninsure, Freeport-McMoRan, Level 3 Communications, Electronic Arts, and Isis Pharmaceuticals Released By InvestorsObserver
PR Newswire - Wed Jul 16, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CISG, FCX, LVLT, EA, and ISIS.
Isis Pharmaceuticals Earns $1 Million from GSK for Advancing ISIS-TTR Rx
PR Newswire - Wed Jul 16, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).
Biotech Equities Technical Momentum -- Research on Organovo, Prana Biotechnology, Isis Pharma, and Pharmacyclics
PR Newswire - Mon Jul 14, 6:04AM CDT
On Friday, July 11, 2014, the NASDAQ Composite ended at 4,415.49, up 0.44%, the Dow Jones Industrial Average advanced 0.17%, to finish the day at 16,943.81, and the S&P 500 closed at 1,967.57, up 0.15%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 712.90, up 0.14%, with the index also advancing 10.01% in the previous three months. Investor-Edge has initiated coverage on the following equities: Organovo Holdings Inc. (NYSE MKT: ONVO), Prana Biotechnology Ltd (NASDAQ: PRAN), Isis Pharmaceuticals Inc. (NASDAQ: ISIS) and Pharmacyclics Inc. (NASDAQ: PCYC). Free technical research on ONVO, PRAN, ISIS and PCYC can be downloaded upon signing up at:
Is This the Crown Jewel of the ISIS Pipeline?
Brian Wilson, The Motley Fool - Motley Fool - Tue Jul 08, 1:01PM CDT
ISIS Pharmaceuticals is a drug developer that is most famous for its RNA interference (RNAi) technology. Although early clinical progress in RNAi was slow due to crippling toxicity and delivery issues, ISIS Pharma (and its peers) have truly refined...
Watch for Isis Pharmaceuticals to Potentially Rebound After Falling 6.71% Yesterday
Comtex SmarTrend(R) - Mon Jul 07, 6:04PM CDT
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $33.03 to a high of $35.36. Yesterday, the shares fell 6.7%, which took the trading range below the 3-day low of $34.51 on volume of 2.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Isis Pharmaceuticals to Speak at Pharmica Consulting's West Coast SharePoint Conference
PRWeb - Mon Jul 07, 4:31AM CDT
As part of its continued service to the industry, Pharmica will host its 11th SharePoint conference in San Diego, CA on September 30 and October 1, 2014. The two-day conference will highlight real-world case studies and feature interactive discussions that help business users better understand how SharePoint can be leveraged to streamline everyday activities.
19.0% Return Seen to Date on SmarTrend Isis Pharmaceuticals Call (ISIS)
Comtex SmarTrend(R) - Wed Jul 02, 5:09PM CDT
SmarTrend identified an Uptrend for Isis Pharmaceuticals (NASDAQ:ISIS) on May 27th, 2014 at $29.71. In approximately 1 month, Isis Pharmaceuticals has returned 19.00% as of today's recent price of $35.35.
Isis Pharmaceuticals earns USD1m pre-licensing payment for Hepatitis B Virus Programme
M2 - Wed Jul 02, 7:39AM CDT
Novel drugs company Isis Pharmaceuticals (NasdaqGS:ISIS) said on Wednesday that it has earned a USD1m for the advancement of the programme to develop antisense drugs to treat hepatitis B virus (HBV) from GlaxoSmithKline (GSK).
Isis Pharmaceuticals Earns $1 Million From GSK for Advancing Hepatitis B Virus Program
PR Newswire - Wed Jul 02, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million payment from GlaxoSmithKline (GSK) related to the advancement of its program to develop antisense drugs to treat hepatitis B virus (HBV).
